[go: up one dir, main page]

NZ756051A - Rescue treatment of post operative nausea and vomiting - Google Patents

Rescue treatment of post operative nausea and vomiting

Info

Publication number
NZ756051A
NZ756051A NZ756051A NZ75605118A NZ756051A NZ 756051 A NZ756051 A NZ 756051A NZ 756051 A NZ756051 A NZ 756051A NZ 75605118 A NZ75605118 A NZ 75605118A NZ 756051 A NZ756051 A NZ 756051A
Authority
NZ
New Zealand
Prior art keywords
amisulpride
use according
antagonist
emetic
patient
Prior art date
Application number
NZ756051A
Other versions
NZ756051B2 (en
Inventor
Robert William Gristwood
Gabriel Fox
Julian Clive Gilbert
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of NZ756051A publication Critical patent/NZ756051A/en
Publication of NZ756051B2 publication Critical patent/NZ756051B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Amisulpride is useful in the treatment of postoperative nausea and/or vomiting in a patient, wherein the patient has already been administered a prophylaxis drug for postoperative nausea and/or vomiting, and wherein the dose of amisulpride is 7.5 to 15 mg. Wherein the first prophylaxis drug is not amisulpride, and the medicament is suitable for administration by IV infusion over a time period of between 20 seconds to 20 minutes to administer a dose of 9.5 to 10.5 mg to the patient.

Claims (15)

CLAIM IS:
1. Use of amisulpride for the manufacture of a medicament for the treatment of postoperative nausea and/or vomiting (PONV) in a patient, wherein the patient has already been administered a non-amisulpride prophylaxis drug for PONV prior to surgery, wherein the medicament is suitable for IV infusion of the amisulpride over a time period of from about 20 seconds up to about 20 minutes, and wherein the dose of amisulpride administered to the patient is 9.5 to 10.5 mg.
2. The use according to claim 1, wherein the prophylaxis drug is not a dopamine-2 (D ) antagonist.
3. The use according to claim 1 or 2, wherein the prophylaxis drug is an anti- emetic selected from a 5HT -antagonist, a corticosteroid, an anti-histamine (H1), an anti-cholinergic, a H -antagonist or a NK -antagonist.
4. The use according to any one of the preceding claims, wherein the medicament is suitable for IV infusion of the amisulpride in combination with another anti-emetic, either separately, sequentially or simultaneously.
5. The use according to claim 4, wherein the another anti-emetic is a 5HT antagonist, an NK antagonist or a steroid.
6. The use according to claim 4 or claim 5, wherein the another anti-emetic is dexamethasone, ondansetron, granisetron, palonosetron, aprepitant, netupitant or rolapitant.
7. The use according to any one of the preceding claims, wherein the amisulpride is substantially in the form of a racemate.
8. Use of amisulpride for the manufacture of a medicament for treating postoperative nausea and/or vomiting (PONV) in a patient, wherein the dose of amisulpride is 9.5 mg to 10.5 mg, wherein the patient has been administered a prophylaxis drug for PONV, undergone a surgical procedure, and experienced PONV, and wherein the prophylaxis drug is not amisulpride.
9. The use according to claim 8, wherein the prophylaxis drug is not a dopamine-2 (D ) antagonist.
10. The use according to claim 8 or 9, wherein the prophylaxis drug is an anti- emetic selected from a 5HT -antagonist, a corticosteroid, an anti-histamine (H1), an anti-cholinergic, a H -antagonist and a NK -antagonist.
11. The use according to any one of claims 8 to 10, wherein the medicament is suitable for IV infusion of the amisulpride in combination with another anti- emetic, either sequentially or simultaneously.
12. The use according to claim 11, wherein the another anti-emetic is a 5HT antagonist, an NK antagonist or a steroid.
13. The use according to claim 11, wherein the another anti-emetic is dexamethasone, ondansetron, granisetron, palonosetron, aprepitant, netupitant or rolapitant.
14. The use according to any one of claims 8 to 13, wherein the amisulpride is substantially in the form of a racemate.
15. The use according to any one of claims 8 to 14, wherein the medicament is suitable for IV infusion of the amisulpride.
NZ756051A 2018-02-09 Rescue treatment of post operative nausea and vomiting NZ756051B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1702250.0A GB201702250D0 (en) 2017-02-10 2017-02-10 Method
PCT/GB2018/050374 WO2018146490A1 (en) 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting

Publications (2)

Publication Number Publication Date
NZ756051A true NZ756051A (en) 2024-04-26
NZ756051B2 NZ756051B2 (en) 2024-07-30

Family

ID=

Also Published As

Publication number Publication date
US11357753B2 (en) 2022-06-14
IL268591B2 (en) 2023-04-01
IL298486B1 (en) 2024-05-01
US12329740B2 (en) 2025-06-17
WO2018146490A1 (en) 2018-08-16
IL298486A (en) 2023-01-01
KR20190111993A (en) 2019-10-02
KR20240001288A (en) 2024-01-03
US12005042B2 (en) 2024-06-11
IL268591B (en) 2022-12-01
JP2023027213A (en) 2023-03-01
BR112019016565A2 (en) 2020-03-31
US20200038369A1 (en) 2020-02-06
JP7526244B2 (en) 2024-07-31
AU2018218310A1 (en) 2019-08-22
AU2024203155B2 (en) 2025-03-13
AU2018218310B2 (en) 2024-02-15
IL298486B2 (en) 2024-09-01
US20230100786A1 (en) 2023-03-30
ZA201905212B (en) 2023-12-20
CA3052535A1 (en) 2018-08-16
EP3579831A1 (en) 2019-12-18
US20240285579A1 (en) 2024-08-29
JP2020506209A (en) 2020-02-27
MX388736B (en) 2025-03-20
GB201702250D0 (en) 2017-03-29
CN110603036A (en) 2019-12-20
EA201991667A1 (en) 2020-02-11
AU2024203155A1 (en) 2024-05-30
JP7333269B2 (en) 2023-08-24
IL268591A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
Pergolizzi Jr et al. Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting
PH12017501097A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
JP2018522920A5 (en)
MY189110A (en) Fast acting orally disintegrating film
AU2024203155B2 (en) Rescue treatment of post operative nausea and vomiting
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
JP2020506209A5 (en)
JOP20190019A1 (en) Pharmaceutical Formula for Treatment of Growth Hormone Deficiency Contains Human Growth Hormone (hGH) Fusion Protein
NZ751972A (en) Treatment of prurigo nodularis
NZ756051B2 (en) Rescue treatment of post operative nausea and vomiting
MX2019010651A (en) Apparatus and methods for administration of a nauseogenic compound from a drug delivery device.
Moradi Farsani et al. Comparison of Ondansetrone, Metoclopramide and Midazolam for PONV prophylaxis in Strabismus surgery
WO2019067768A3 (en) Fixed dose combination formulations for treating pain
JPWO2022008901A5 (en)
Sharma et al. Managing Hyperemesis in the Era of Concurrent and Sequential Chemo-radiation
Butcher Clinical Effects of 5-HT, Antagonists in Treating Nausea and Vomiting
NZ796242A (en) Rescue treatment of post operative nausea and vomiting
Pereira-Santos et al. Effects of co-administered dexamethasone and nimesulid on pain, swelling and trismus following third molar surgery
MX2022013103A (en) Novel multiparticulate pharmaceutical composition of tamsulosin and solifenacin.
Gupta et al. Effect of Ultra-Low-Dose-Naloxone, added to fentanyl and lidocaine for peribulbar anesthesia
MX2019009733A (en) 3'deamino-3'-(2"-pyrroline-1"-yl)-5-imino-13-deoxyanthracyclines and methods of preparation.
ZA202102392B (en) Medicament for therapeutic treatment and/or improvement of sepsis accompanied by coagulopathy
RU2015128914A (en) LORAZEPAM COMPOSITIONS WITH CONTROLLED RELEASE
Chuah et al. Second-line Rescue Anti-Helicobacter Pylori Therapy without Bismuth Salts: A Prospective Randomized Controlled Study Comparing Levofloxacin–based and Tetracycline-based Triple Therapy

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 FEB 2026 BY COMPUTER PACKAGES INC

Effective date: 20250117